These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 22786460)

  • 1. Office-based opioid dependence treatment.
    Colson J; Helm S; Silverman SM
    Pain Physician; 2012 Jul; 15(3 Suppl):ES231-6. PubMed ID: 22786460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification.
    Helm S; Trescot AM; Colson J; Sehgal N; Silverman S
    Pain Physician; 2008; 11(2):225-35. PubMed ID: 18354714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.
    Daitch J; Frey ME; Silver D; Mitnick C; Daitch D; Pergolizzi J
    Pain Physician; 2012 Jul; 15(3 Suppl):ES59-66. PubMed ID: 22786462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid dependence treatment, including buprenorphine/naloxone.
    Raisch DW; Fye CL; Boardman KD; Sather MR
    Ann Pharmacother; 2002 Feb; 36(2):312-21. PubMed ID: 11847954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statement of the American Society Of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction.
    Kraus ML; Alford DP; Kotz MM; Levounis P; Mandell TW; Meyer M; Salsitz EA; Wetterau N; Wyatt SA;
    J Addict Med; 2011 Dec; 5(4):254-63. PubMed ID: 22042215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use and misuse of opioid replacement therapies: a Queensland study.
    Smirnov A; Kemp R
    Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The science and practice of medication-assisted treatments for opioid dependence.
    Pecoraro A; Ma M; Woody GE
    Subst Use Misuse; 2012; 47(8-9):1026-40. PubMed ID: 22676570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consensus statement on office-based treatment of opioid dependence using buprenorphine.
    Fiellin DA; Kleber H; Trumble-Hejduk JG; McLellan AT; Kosten TR
    J Subst Abuse Treat; 2004 Sep; 27(2):153-9. PubMed ID: 15450648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction.
    Veilleux JC; Colvin PJ; Anderson J; York C; Heinz AJ
    Clin Psychol Rev; 2010 Mar; 30(2):155-66. PubMed ID: 19926374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing opioid addiction with buprenorphine.
    Donaher PA; Welsh C
    Am Fam Physician; 2006 May; 73(9):1573-8. PubMed ID: 16719249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone.
    Seifert J; Metzner C; Paetzold W; Borsutzky M; Passie T; Rollnik J; Wiese B; Emrich HM; Schneider U
    Pharmacopsychiatry; 2002 Sep; 35(5):159-64. PubMed ID: 12237786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bupreorphine:a new pharmacotherapy for opioid addictions treatment.
    Stock C; Shum JH
    J Pain Palliat Care Pharmacother; 2004; 18(3):35-54. PubMed ID: 15364630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using buprenorphine for outpatient opioid detoxification.
    Manlandro JJ
    J Am Osteopath Assoc; 2007 Sep; 107(9 Suppl 5):ES11-6. PubMed ID: 17908825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.
    Kögel B; Christoph T; Strassburger W; Friderichs E
    Eur J Pain; 2005 Oct; 9(5):599-611. PubMed ID: 16139189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid drugs in maintenance and detoxification treatment of opiate addiction; addition of buprenorphine and buprenorphine combination to list of approved opioid treatment medications. Interim final rule.
    Substance Abuse and Mental Health Services Administration (SAMHSA), Department of Health and Human Services
    Fed Regist; 2003 May; 68(99):27937-9. PubMed ID: 12762334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid dependence: rationale for and efficacy of existing and new treatments.
    Fiellin DA; Friedland GH; Gourevitch MN
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S173-7. PubMed ID: 17109303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.
    Stein BD; Gordon AJ; Sorbero M; Dick AW; Schuster J; Farmer C
    Drug Alcohol Depend; 2012 Jun; 123(1-3):72-8. PubMed ID: 22093488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buprenorphine for office-based treatment of patients with opioid addiction.
    Manlandro JJ
    J Am Osteopath Assoc; 2005 Jun; 105(6 Suppl 3):S8-13. PubMed ID: 16118361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine for opioid dependence.
    Milne M; Crouch BI; Caravati EM
    J Pain Palliat Care Pharmacother; 2009; 23(2):153-5. PubMed ID: 19492216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Opioid tolerance and dependence--pharmacological aspects].
    Jaba IM; Luncanu I; Mungiu OC
    Rev Med Chir Soc Med Nat Iasi; 2001; 105(3):444-50. PubMed ID: 12092171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.